Biotech · Private company
Aragon Pharmaceuticals, Inc.
Track this companyFree. Adds Aragon Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials115 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- 74-80 Grays (units of radiation)Phase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Abiraterone acetatePhase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Androgen Deprivation Therapy (ADT)Phase 3 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ApalutamidePhase 3 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ApalutamidePhase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- BicalutamidePhase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- GnRH (agonist)Phase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- ARN-509Phase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ARN-509 (Phase 1)Phase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ARN-509 (Phase 2)Phase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- LHRH AgonistPhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Abiraterone acetatePhase 1 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ApalutamidePhase 1 · Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- JNJ-56021927Phase 1 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- JNJ-56021927Phase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 1 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc StudyPHASE1 · COMPLETED · started Dec 18, 2015ClinicalTrials.gov NCT02578797 · fetched Nov 12, 2026
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPCPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 27, 2015ClinicalTrials.gov NCT02489318 · fetched Nov 12, 2026
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 19, 2015ClinicalTrials.gov NCT02531516 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic FunctionPHASE1 · COMPLETED · started Aug 13, 2015ClinicalTrials.gov NCT02524717 · fetched Nov 12, 2026
- An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 26, 2014ClinicalTrials.gov NCT02257736 · fetched Nov 12, 2026
- A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 9, 2014ClinicalTrials.gov NCT02123758 · fetched Nov 12, 2026
- ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone AcetatePHASE1 · COMPLETED · started Apr 1, 2014ClinicalTrials.gov NCT02106507 · fetched Nov 12, 2026
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 14, 2013ClinicalTrials.gov NCT01946204 · fetched Nov 12, 2026
- The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate CancerPHASE2 · COMPLETED · started Mar 4, 2013ClinicalTrials.gov NCT01790126 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetatePHASE1 · COMPLETED · started Feb 5, 2013ClinicalTrials.gov NCT01792687 · fetched Nov 12, 2026
- Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)PHASE1_PHASE2 · COMPLETED · started Jul 26, 2010ClinicalTrials.gov NCT01171898 · fetched Nov 12, 2026